ArcticZymes Technologies exclusively licenses novel DNA assembly




Tromsø, Norway, 08[th] December 2022 - ArcticZymes Technologies ASA (OSE: AZT)
exclusively licenses novel DNA assembly technology from UiT The Arctic
University of Norway

ArcticZymes Technologies (AZT) has signed an exclusive licensing agreement with
UiT The Arctic University of Norway (UiT) for a novel DNA assembly technology.
The technology was developed by researchers at UiT and is based on unique heat
-labile enzymes identified by marine bioprospecting in the Arctic. The patent
-pending technology comprises novel enzymes with tailor-made characteristics for
controlled and efficient assembly of multiple DNA fragments.

DNA assembly is a work-horse technology serving a growing demand for gene- and
vector- constructs, enabling innovation in areas such as synthetic biology and
in the development of therapeutics. Synthetic biology is a growing
multidisciplinary field seeking to take advantage of synthetic genes and
genomes, generating new and improved biological systems to solve challenges in
medicine, manufacturing, and applied markets. The global synthetic biology
market was estimated at $9.6 billion in 2021 and projected to grow at a compound
annual growth rate (CAGR) of 26%.

By acquiring this technology, the Company will expand its offering towards new
and existing customers in both the molecular tools and biomanufacturing
businesses.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"DNA assembly technologies are being utilised by biomanufacturers and service
providers, or offered as molecular tools for integration into application
workflows. The technology licensed by AZT will circumvent limitations in current
technologies.

We are delighted to enter into a further agreement with UiT. It builds on our
long-term partnership which has been successful in commercialising multiple
discoveries."

UiT The Arctic University of Norway, Head of Department, Department of
chemistry, Annette Bayer said:

"This technology is a great achievement for UiT, our researchers, collaborators,
and the Norwegian Research Council, and can enable technology advances in
important areas in the future. We are happy to have entered an agreement with an
experienced partner like ArcticZymes to make the technology available".
Redigert 08.12.2022 kl 08:54 Du må logge inn for å svare
xjack
08.12.2022 kl 15:51 1263

Man bør vel ikke utelukke at AZT pynter seg staseligere for å stå best mulig rustet i forbindelse med feks. en kommende merger?
JosefK
08.12.2022 kl 17:08 1192


Er ikke bruden staselig nok 💃😗🤩??

Jeg kan selvfølgelig ikke vurdere dette verktøyet opp mot andre, men jeg har forsøkt å danne meg et bilde av hvilke handler som gjøres og finner deals opp i 100 mUSD klassen.

Det jeg imidlertid kan si med sikkerhet er at det vil passe big pharma veldig godt. Sanofi ligger i bakhodet.

Ut over det, tror jeg man må smøre litt tålmodighetskrem på denne transaksjonen.
JosefK
09.12.2022 kl 00:39 973


Jeg blir bare mer og mer sikker på at Atle Noralf Larsen er det riktige sporet i UiT. Han har dette patentet liggende klart og fler til som jeg er mer usikker på passer inn i denne sammenhengen.

https://patents.google.com/patent/WO2021064115A1/en

Yzf R1
09.12.2022 kl 08:38 837

Går veien dette.Et klapp til ledelsen bør de få de ,har vært gode de sist året.

ArcticZymes Technologies upscales the production of ArcticZymes Proteinase and launches ArcticZymes Proteinase Glycerol FREE

Tromsø, Norway, 9th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) upscales the production of ArcticZymes Proteinase and launches ArcticZymes Proteinase Glycerol FREE

ArcticZymes Technologies (AZT) has successfully upscaled the production of ArcticZymes Proteinase. This will allow the Company to meet growing demand from new and existing customers, thereby strengthening the Company´s position as a supplier of critical components in molecular diagnostics and biomanufacturing applications.

Additionally, AZT has launched a glycerol-free formulation of the proteinase. This was facilitated by the upscaling of the proteinase enzyme. This glycerol-free formulation will enable the Company to support customers requiring a lyophilization compatible formulation of the proteinase for use in high throughput molecular diagnostic workflows.

Together the upscaled production capacity and addition of a glycerol-free formulation, greatly increases the market reach for ArcticZymes Proteinase products, both being instrumental factors for sales growth while ensuring a reliable and relevant product offering to existing and new customers.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

“The novel features of ArcticZymes Proteinase have already enabled customers to circumvent technical barriers that other enzymes such as Proteinase K cannot overcome in molecular diagnostics workflows. In biomanufacturing there is a growing interest in ArcticZymes Proteinase for potential use in gene therapy related applications.”

draugen
09.12.2022 kl 09:06 779

Ser ut til at AZT har startet med åpning av lukene i julekalenderen! I morgen ønsker jeg meg M&A melding, det ville gitt meg den gode julestemninga :-)
Carrera
09.12.2022 kl 10:52 658

AZT er en av 6 i dagens "hold deg unna" aksjer i FA
JosefK
09.12.2022 kl 11:26 582


Hold deg unna da vel. 🤷

BioNord
09.12.2022 kl 11:28 569

Ja dagens melding var jo skikkelig «urovekkende»
Økende etterspørsel fra nye og eksisterende kunder burde jo virkelig få alarmklokkene til å ringe.